STX — Shield Therapeutics Share News
0.000.00%
Last trade - 00:00- £93.75m
- £105.73m
- $32.18m
- 26
- 10
- 100
- 38
REG - Shield Therapeutics - ACCRUFeR® assigned Priority Review in US by FDA
AnnouncementREG - Shield Therapeutics - Data published -European Journal of Heart Failure
AnnouncementREG - Shield Therapeutics - Interim results for the six months ended 30 Jun 25
AnnouncementREG - Shield Therapeutics - Q2 2025 Trading Update
AnnouncementREG - Shield Therapeutics - Result of AGM
AnnouncementREG - Shield Therapeutics - Audited results for the year ended 31 Dec 2024
AnnouncementREG - Shield Therapeutics - Licence Agreement in Japan for ACCRUFeR®
AnnouncementREG - Shield Therapeutics - Q1 2025 Trading Update
AnnouncementREG - Shield Therapeutics - ACCRUFeR® launched in Canada
AnnouncementREG - Shield Therapeutics - PDMR Transaction Notification
AnnouncementREG - Shield Therapeutics - Grant of Share Options
AnnouncementREG - Shield Therapeutics - Unaudited full year trading update
AnnouncementREG - Shield Therapeutics - Anders Lundstrom appointed CEO
AnnouncementREG - AIM - AIM Notice - 30/12/2024
AnnouncementREG - Shield Therapeutics - Result of General Meeting & Total Voting Rights
AnnouncementREG - Shield Therapeutics - Results of RetailBook Offer
AnnouncementREG - Shield Therapeutics - RetailBook Offer
AnnouncementREG - Shield Therapeutics - Subscription by AOP Health to raise US$10 million
AnnouncementREG - Shield Therapeutics - Business Update
Announcement